Medical and Pharmaceutical Biopharma operator Zai Lab surges to 16-month high on lung cancer drug trial results Analysts at Cantor Fitzgerald and JP Morgan Chase & Co recently gave the company an overweight rating Rowan DunneOctober 25, 2024